Table 1.

Characterics of Subjects >15% Increased MA use with Treatment

		Sertraline	Placebo	P Value
Demographics
>15% Increased MA use n(%)		13(21)	5(7)	0.03*
Age		37.6(9.5)	32.1(9.9)	0.3
Gender	Male n(%)	8(61)	2(40)	0.72
Ethnicity	White n(%)	11(85)	3(60)	0.53
Lifetime MA Use (years)		13.1(7.8)	13.2(11.8)	0.98
Fraction of MA-Positive		0.30(0.26)	0.20(0.36)	0.94
Urine in Baseline
Assigned to Contingency Management		7(54)	2(40)	0.84
RP Factors
Baseline SCID Global Assessment of Functioning		48.2(8.2)	53.0(9.2)	0.29
Baseline ASI Drug Composite Score		0.17(0.04)	0.16(0.04)	0.66
Week 13 Clinical Global Impression		5.7(0.7)	5.5(0.6)	0.61
Average MA craving weeks 8–13		4.6(1.7)	2.4(1.8)	0.04*
SCL-90 Positive Symptoms Total scale week 8		7.5(14.8)	13.8(11.1)	0.45

RP Factors: Factors identified as contributing to >15% Increased MA use with treatment by Recursive Partitioning

Categorical variables (Gender, Ethnicity,>15% Increased MA use, # of times Detox, Contingency Management assignment) were analyzed by chi-square test

Continuous Variables (all others) were analyzed by ANOVA, numbers tabled are means (s.d.) Factors showing significant group difference (p<0.05) highlighted in bold with asterix